Table 3.
Lipid and lipoprotein levels (mg/dl), and body mass index (kg/m2) according to the APOE genotypes and sex
| Males (n = 260) | Females (n = 242) | |||||||
| Genotype | ε2/ε3 | ε3/ε3 | ε3/ε4 | P value | ε2/ε3 | ε3/ε3 | ε3/ε4 | P value |
| n (%) | 22 (8.5) | 186 (71.6) | 52 (19.9) | 21 (8.5) | 175 (72.6) | 46 (18.9) | ||
| TC** | 144.2* ± 34.4 | 157.9 ± 24.8 | 160.6 ± 26.8 | <0.05 | 160.8 ± 24.7 | 169.1 ± 25.1 | 177.0 ± 30.8 | NS |
| HDLc** | 53.0 ± 8.6 | 51.4 ± 9.6 | 49.8 ± 10.3 | NS | 65.5* ± 11.1 | 58.6 ± 11.0 | 58.5 ± 13.1 | NS |
| LDLc** | 77.2† ± 28.6 | 92.7 ± 22.9 | 95.3 ± 23.8 | <0.01 | 83.2† ± 24.7 | 97.5 ± 21.9 | 103.4 ± 26.1 | <0.01 |
| TG** | 69.7 ± 28.7 | 69.4 ± 28.1 | 77.5 ± 39.0 | NS | 60.4 ± 22.1 | 64.4 ± 26.1 | 68.0 ± 30.0 | NS |
| apoA** | 115.9 ± 15.6 | 118.1 ± 17.3 | 114.5 ± 16.3 | NS | 141.7† ± 15.6 | 125.7 ± 17.9 | 128.9 ± 23.3 | <0.01 |
| apoB** | 55.6† ± 15.8 | 68.0 ± 13.0 | 68.8 ± 16.4 | <0.001 | 59.3† ± 11.7 | 70.1 ± 12.9 | 73.9 ± 16.1 | <0.001 |
| Lp(a)** | 23.1 ± 33.4 | 31.0 ± 35.1 | 33.1 ± 41.9 | NS | 14.3 ± 15.3 | 33.0 ± 40.3 | 37.6 ± 38.5 | NS |
| TC-HDLc | 91.1* ± 31.6 | 106.6 ± 24.3 | 110.8 ± 27.7 | <0.01 | 95.3* ± 25.5 | 110.4 ± 24.0 | 118.5 ± 30.5 | <0.01 |
| TC/HDLc | 2.7* ± 0.7 | 3.2 ± 0.7 | 3.4 ± 0.9 | <0.01 | 2.5* ± 0.7 | 3.0 ± 0.6 | 3.1 ± 0.8 | <0.01 |
| apoB/apoA | 0.5* ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.2 | <0.01 | 0.4† ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.2 | <0.001 |
| BMI | 20.9 ± 3.9 | 22.2 ± 3.8 | 22.4 ± 4.0 | NS | 21.5 ± 3.9 | 21.7 ± 3.6 | 21.8 ± 3.4 | NS |
Values are expressed as mean ± standard deviation, otherwise stated.
P value from ANOVA, adjusted for mass significance.
*P < 0.05; †P < 0.01 for ε2/ε3 vs ε3/ε3 (Tukey test).
TC indicates total cholesterol; HDLc, high density liprotein cholesterol; LDLc, low density lipoprotein cholesterol; TG, triglycerides; Apo, apolipoprotein; Lp(a), lipoprotein (a); BMI, body mass index; NS, not significant.
**Analyses were performed on log transformed data, but non-transformed data are presented in the table.